Company intelligence / Profile preview

DemeRx

Miami, Florida, United Statesdemerx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

DemeRx is conducting Phase 1 clinical trials for DMX-1001 (oral noribogaine) for Alcohol Use Disorder. The company has completed three Phase 1 pharmacokinetic studies showing DMX-1001 has a favorable safety profile with no serious adverse events reported. A new Phase 1 study is enrolling healthy volunteers with topline data from the fourth cohort anticipated in Q1 2025. The company is advancing dose selection for a Phase 2 trial for AUD treatment[4].

Therapeutic areas: Psychiatry
Modalities: Small molecules (noribogaine/DMX-1001)
Industry: Biotech

Drug pipeline

2 assets

DMX-2001

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on DemeRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DemeRx.

Explore the full profile